(SNTI) Senti Biosciences, Inc. Business Model Canvas Research

Supply chain vendors are key for Senti Biosciences, Inc. because specialized suppliers provide vectors, reagents, disposables, and GMP-grade raw materials needed for cell and gene therapy work. These inputs must be lot-traceable and consistent, since a single failed batch can add 3-6 months of delay and raise clinical risk.

• GMP inputs must stay consistent
• Lot traceability cuts batch risk
• Reliable vendors protect timelines

For Senti Biosciences, Inc., dependable vendors help keep manufacturing stable and lower the chance of trial setbacks, supply gaps, and costly rework.

Investors, grant makers, and strategic partners fund Senti Biosciences, Inc.'s long biotech path, where cell therapy programs often need 5-10 years and repeated rounds before product revenue. These partners help finance R&D across multiple pipeline assets, easing the cash burn that comes with preclinical work, IND steps, and early clinical studies.

• Bridges pre-revenue R&D
• Reduces dilution pressure
• Funds multiple pipeline assets

Senti Biosciences, Inc. uses clinical development to move SENTI-202, SENTI-301, and SENTI-401 into human testing. The work covers protocol design, enrollment support, safety review, and data analysis, and it is the company’s main proof-of-concept path across 3 active programs.

• 3 programs: SENTI-202, SENTI-301, SENTI-401
• Designs and runs study protocols
• Supports enrollment and safety review
• Turns trial data into proof-of-concept evidence

Senti Biosciences, Inc. uses GMP scale-up to turn engineered cells into reproducible release lots, while regulatory work builds the CMC package, quality system, and FDA contact trail needed for INDs. The FDA’s IND review clock is 30 days, so batch control, docs, and agency replies must be tight from the start.

• GMP lots must match the same specs every run
• Regulatory files support IND filing in 30 days
• Quality systems reduce delay and rework

Senti Biosciences, Inc. depends on a scientific team of scientists, engineers, and translational experts to build its synthetic biology, immunology, cell therapy, and oncology platform. In a clinical-stage biotech model with no product sales yet, human capital is the core asset because progress depends on specialized know-how, fast experimentation, and clean translation from lab work to clinic.

• Scientists drive platform design and discovery
• Engineers support build and test cycles
• Translational experts bridge lab and clinic
• Biotech value depends on rare expertise

Senti Biosciences, Inc. is headquartered in South San Francisco, California, the core of the Bay Area biotech cluster, where more than 200 life science companies operate nearby and the city has supported biotech for decades. This location gives the Company access to talent, lab vendors, and shared research infrastructure for corporate, scientific, and development work.

• South San Francisco HQ anchors biotech hiring
• Cluster improves vendor and lab access
• Facilities support R&D and operations

Senti Biosciences, Inc.’s broad cancer coverage spans liquid and solid tumors, including AML, HCC, and CRC, so one platform can address multiple disease settings. That widens relevance across large oncology markets: AML has about 20,000 new U.S. cases a year, CRC about 153,000, and liver cancer remains one of the deadliest solid-tumor areas.

• AML, HCC, and CRC in one pipeline
• Fits both liquid and solid tumors
• Boosts market reach and platform reuse

Senti Biosciences, Inc.'s multi-antigen, multi-armed logic, used in SENTI-301 and other programs, goes beyond single-target CARs by combining tumor recognition and control signals in one design. That matters in heterogeneous cancers, where cells can lose one marker and still evade treatment; multi-armed systems are built to reduce that escape risk and sharpen response control.

• Targets more than one tumor signal
• Can better catch mixed cancer cells
• Helps control response, not just attack

Senti Biosciences, Inc. must keep regulators and study investigators aligned on 3 live tracks: safety data, manufacturing data, and protocol changes. In advanced therapy trials, that steady review builds trust, and trust matters because one late change can affect enrollment, site work, and FDA or IRB timing.

• Safety, CMC, and protocol updates need ongoing review.
• Clear regulator contact reduces trial friction.
• Transparency supports advanced therapy credibility.

Senti Biosciences keeps investor reporting tight because, as a public biotech, the market watches pipeline updates, financings, and clinical milestones. Revenue is still development-driven, so shareholder trust depends more on clear cash, trial, and timeline disclosure than on sales.

• Regular updates shape expectations
• Financings signal runway
• Milestones move valuation
• No product sales yet

Senti Biosciences, Inc. uses its corporate website, press releases, and SEC filings to share pipeline and financial updates, including the 2025 Form 10-K and 2026 quarterly reports. As a listed biotech, these are the main public sources for investors, partners, and media.

• Website: pipeline and news
• SEC filings: audited financials
• Press releases: key milestones

Senti Biosciences, Inc. uses direct outreach to pharma, biotech, and research groups to win licenses, co-dev deals, and strategic funding. This channel matters most for non-commercial biotech, where partnership income can support R&D before product sales.

• Targets pharma, biotech, research groups
• Drives licensing and collaboration
• Supports strategic funding

Oncology treatment centers are the gatekeepers for Senti Biosciences, Inc. cell therapies: hospitals, infusion centers, and specialty cancer programs pick patients, give the treatment, and watch for safety issues. These institutional buyers matter because CAR-T use in the U.S. still runs through a limited network of certified centers, which keeps access and protocol control tight.

• Patient selection and eligibility
• Infusion and follow-up monitoring
• Safety reporting and adverse-event care

Pharma and biotech partners can license Senti Biosciences, Inc.'s platform or co-develop indication-specific programs, buying access to gene circuit control, CAR-NK know-how, and pipeline data. This segment can create upfront fees plus milestone income, which matters in a market where deal value often beats near-term sales for early-stage cell therapy platforms.

• License the platform or co-develop programs.
• Buy gene circuit and CAR-NK expertise.
• Drive upfront cash and milestone value.

Manufacturing and quality are a major cost driver for Senti Biosciences, Inc. because GMP runs, release testing, and process optimization require skilled labor, cleanroom capacity, and heavy QC oversight. In cell therapy, manufacturing can consume a large share of cost of goods, and off-the-shelf CAR-NK products still need full batch release, identity, purity, potency, and sterility controls.

• GMP production is labor heavy
• Release testing slows batch turnover
• Quality systems stay fixed-cost heavy
• Process tuning adds extra spend

Senti Biosciences' G&A and IP costs cover finance, legal, investor relations, and public-company reporting, plus patent prosecution and freedom-to-operate work. This spend supports day-to-day operations and protects the platform, so it sits at the core of corporate control and IP defense.

• Finance and legal overhead
• Investor relations and reporting
• Patent prosecution costs
• Freedom-to-operate work

Senti Biosciences, Inc. can use grant funding as a non-dilutive revenue stream for oncology and cell therapy R&D, which matters because these programs often take years before any product cash arrives. Grants from government agencies and foundations can help extend runway and cut reliance on equity raises, especially when internal cash is under pressure.

• Non-dilutive R&D cash
• Supports long timelines
• Reduces dilution risk

Senti Biosciences, Inc. has 3 near-term value drivers here: SENTI-202, SENTI-301, and SENTI-401. If any are approved, Senti Biosciences, Inc. could earn therapy sales or royalties, with commercial revenue likely flowing through specialty oncology channels; this is the main long-term value capture path.

• 3 programs can drive future sales
• Revenue may come as royalties
• Specialty oncology is the launch path